(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Vote In favor of Your Favored Video Conferencing Administration- A Gastronomic Experience in Healthy Enjoyments: A Survey of \Nutritious and Tasty\ Solid Cooking Recipe Book
- 5 Movies That Leaving an Imprint with Inventive Innovation
- How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- German hauliers warn soaring energy prices may soon impact consumers
- Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- NASA's Artemis 2 astronauts are cruising to the moon. So why are they doing CPR tests today?
- How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- Canada's Friendly Sunshine Coast City Is An Outdoor Playground Perfect For Hiking And Paddling
